Showing results (371-380 of 1,831) with videos related to

Sort By:
Pageof 184
ESMO Open|March 5, 2026
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trialsK Jhaveri, F C Bidard, K Kalinsky, et al.
ESMO Open|February 7, 2024
The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot studyL Yi, Z Ning, L Xu, et al.
ESMO Open|February 20, 2024
Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trialC Fan, Z Jiang, C Teng, et al.
ESMO Open|February 22, 2024
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)N Lakhani, R Cosman, U Banerji, et al.
ESMO Open|March 22, 2024
Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGEE Cartwright, S Slater, C Saffery, et al.
ESMO Open|February 16, 2024
Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learnedJ S W Borgers, A W van Schijndel, J V van Thienen, et al.
ESMO Open|February 22, 2024
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencingT Takeshita, T Iwamoto, N Niikura, et al.
ESMO Open|March 12, 2024
Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trialJ Tabernero, J Taieb, M Fakih, et al.
ESMO Open|March 12, 2024
Aggressive anticancer treatment in the last 2 weeks of lifeN Golob, T Oblak, L Čavka, et al.
ESMO Open|March 9, 2024
Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese populationQ Lu, N Wang, K Jiang, et al.
Pageof 184